Favrille, Inc. (NASDAQ:FVRL) today announced that, on September 16, 2008, it received a staff determination letter from The Nasdaq Stock Market ("Nasdaq") formally notifying the Company that it had not maintained a minimum $10,000,000 stockholders' equity nor submitted a sufficient plan to obtain compliance as required for continued listing on the Nasdaq Global Market under Marketplace Rule 4450(a)(3). Unless the Company appeals the determination and requests a formal hearing with the Nasdaq Listing Qualifications Panel, trading of the Company's common stock on the Nasdaq Global Market will be suspended at the opening of business on September 25, 2008 and a Form 25-NSE will be filed with the Securities and Exchange Commission ("SEC") which will remove the Company's common stock from listing and registration on Nasdaq. The Company does not currently plan to appeal the staff determination. If the Company does not appeal the staff determination, its common stock may not be immediately eligible to trade on the OTC Bulletin Boards or the "Pink Sheets." The Company's common stock may become eligible to trade on the OTC Bulletin Boards or the "Pink Sheets" if a market maker makes an application to register in and quote the common stock in accordance with SEC Rule 15c2-11 and such application (a "Form 211") is cleared. Only a market maker may file a Form 211. It is the Company's goal to have its common stock listed on the OTC Bulletin Boards. The Company is currently in discussions with a market maker to submit the Form 211 application on its behalf.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.